A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 900 participants.

Also called NCT07662135

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 900 participants (planned count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07662135
  • EU CT 2025-523940-12-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Bulgaria, China, Denmark, Germany, India, Japan, Malaysia, Mexico, Spain, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07662135. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-06 (actual); primary completion 2028-07-13 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
Acronym
Eluminate-4
Condition
Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes With Chronic Kidney Disease
Intervention (Drug)
Elecoglipron
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct07662135
Content hash
c275863d028687e532b7b84389db172122d0b444e7711bec286ceb61810b72be